Perhaps according to a report from Stat News:
A groundbreaking clause in a new deal between the Department of Health and Human Services and the pharmaceutical company Regeneron marks the first time the Biden administration has directly used its leverage to challenge drugmakers’ list prices, experts told STAT.
The contract between Regeneron and the government requires that the list price for a future monoclonal antibody drug to prevent Covid-19 is the same or lower in the United States as in other high-income countries. The release doesn’t explain which countries the government will be comparing prices with, or how pricing data will be determined.
To get up to speed on reference pricing, see my previous posts on the topic:
- Definition: What is reference pricing?
- IRA: Will Medicare use reference pricing to negotiate drug prices under the IRA?
- Reference pricing around the world: How countries have implemented reference pricing in practice.
- Best practices for implementation: How do do external reference pricing.
- Cell and gene therapies: International Reference Pricing for Cell and Gene Therapies
- Reference price to gross or net cost? International Reference Pricing: List vs. Net Pricing issues
- Predicted US price impacts: Empirical estimates of the likely impact of international reference pricing on US drug prices.